Novo Nordisk plans to launch at least five multi-blockbuster drugs by 2030 and is targeting pipeline drug sales of $23 billion by 2035. Continue Reading
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.